ArticleNutrients2018
l-Glutamine Attenuates DSS-Induced Colitis via Induction of MAPK Phosphatase-1.
Article in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03917095 (Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing: A Multicenter, Randomized, Controlled Trail
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Preclinical evidence for luteolin in ulcerative colitis: a meta-analysis and systematic review.Frontiers in pharmacology · 2025Pooled it
- Dual Beneficial Effects of Topical l-Glutamine on Oral Mucositis in 5-Fluorouracil-Treated Mice.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Article
- Plasma metabolomic and lipidomic profiling reveals distinct molecular signatures and time-dependent remodeling in ulcerative colitis.BMC gastroenterology · 2026Article
- Article
- L-Glutamine attenuates peritoneal fibrosis developed in 5-Fluorouracil-treated mice.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- α, δ‑ACS pharmacology & translational science · 2025Article
- Leucine-Enriched Diet Reduces Fecal MPO but Does Not Protect Against DSS Colitis in a Mouse Model of Crohn's Disease-like Ileitis.International journal of molecular sciences · 2024Article
- The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases.Cells · 2024Review
- Identification of subclusters and prognostic genes based on GLS-associated molecular signature in ulcerative colitis.Scientific reports · 2024Article
- Causal effects of circulating glutamine on colitis, IBD, and digestive system cancers: a Mendelian randomisation study.Journal of Cancer · 2024Article
- Gastrodin Attenuates Colitis and Prevents Tumorigenesis in Mice by Interrupting TLR4/MD2/NF-κB Signaling Transduction.Anti-cancer agents in medicinal chemistry · 2024Article
- Glutaminolysis is a Potential Therapeutic Target for Kidney Diseases.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Observational
- Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.Cell reports · 2023Article
- Protective Effect ofFoods (Basel, Switzerland) · 2023Article
- Luteolin alleviates ulcerative colitis in rats via regulating immune response, oxidative stress, and metabolic profiling.Open medicine (Warsaw, Poland) · 2023Article
- The reduced SCFA-producing gut microbes are involved in the inflammatory activation in Kawasaki disease.Frontiers in immunology · 2023Article
- L-Glutamine alleviates osteoarthritis by regulating lncRNA-NKILA expression through the TGF-β1/SMAD2/3 signalling pathway.Clinical science (London, England : 1979) · 2022Article
- Glutamine deficiency shifts the asthmatic state toward neutrophilic airway inflammation.Allergy · 2022Article
- The mitigative effect of ovotransferrin-derived peptide IQW on DSS-induced colitis via alleviating intestinal injury and reprogramming intestinal microbes.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a multifactorial inflammatory disease of the small intestine and colon. Many investigators have reported that l-glutamine (Gln) therapy improves outcomes of experimental colitis models, although the mechanism is not fully understood. Regarding the anti-inflammatory properties of Gln, we have shown that Gln can effectively deactivate cytosolic phospholipase A₂ (cPLA₂) by rapid induction of MAPK phosphatase (MKP)-1. In this study, we explore the possibility that Gln ameliorates dextran sulfate sodium (DSS)-induced colitis via MKP-1 induction, resulting in inhibition of cPLA₂, which has been reported to play a key role in the pathogenesis of IBD. Oral Gln intake attenuated DSS-induced colitis. Gln inhibited cPLA₂ phosphorylation, as well as colonic levels of TNF-α and leukotriene (LT)B₄. Gln administration resulted in early and enhanced MKP-1 induction. Importantly, MKP-1 small interfering RNA (siRNA), but not control siRNA, significantly abrogated the Gln-mediated (1) induction of MKP-1; (2) attenuation of colitis (colon length, histological abnormality, and inflammation; and (3) inhibition of cPLA₂ phosphorylation and colonic levels of TNF-α and LTB₄. These data indicated that Gln ameliorated DSS-induced colitis via MKP-1 induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.